News for the Multiple Sclerosis Community

Acorda Multiple sclerosis Drug Wins Priority FDA Review

The subject basically says it all.

The FDA has granted priority review status to the experimental MS drug called Fampridine-SR.

This reflects the Acorda press release issued on same date. Apparently the priority status essentially allows the review process to be completed at nearly the same time as the first review would have been completed if the refusal hadn't happened. Here's hoping that they beat the October target!